Company intelligence / Profile preview
Ikarovec
- Ownership
- Private
- Development stage
- Preclinical
Overview
Ikarovec has developed a unique bicistronic gene therapy approach targeting complex eye diseases such as AMD. Their preclinical data suggest superiority over current and in-development treatments. The company aims to provide a one-time treatment that could offer lifelong benefit and reduce the burden of frequent injections required by current standards of care. They have raised £8M in seed funding and are seeking Series A investment to advance into clinical trials.
- Therapeutic areas
- Ophthalmology
- Modalities
- Gene therapy
- Industry
- Biotech
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Ikarovec.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ikarovec.